Safety and Efficacy Study of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy

Eligibility:  Adults over the age of 18 with Immune-Mediated Necrotizing Myopathy and are positive for HMGCR or SRP autoantibodies

Contact:  trials@rapharma.com

Locations recruiting:
UCLA (Los Angeles, CA), UC-Irvine (Orange, CA), USF (Tampa, FL), KUMC (Kansas City, KS), Brigham and Women’s Hospital (Boston, MA), Northwell Health Neuroscience Institute (Great Neck, NY), Ohio State University (Columbus, OH), UPenn (Philadelphia, PA), Wesley Neurology Clinic (Memphis, TN), University College London Hospitals NHS (London, United Kingdom), and Salford Royal NHS (Manchester, United Kingdom)